SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla advances on getting EIR from USFDA for Invagen manufacturing facility

28 Jan 2020 Evaluate

Cipla is currently trading at Rs. 466.90, up by 2.25 points or 0.48% from its previous closing of Rs. 464.65 on the BSE.

The scrip opened at Rs. 466.00 and has touched a high and low of Rs. 467.45 and Rs. 459.45 respectively. So far 37738 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 585.50 on 27-May-2019 and a 52 week low of Rs. 389.55 on 11-Oct-2019.

Last one week high and low of the scrip stood at Rs. 480.00 and Rs. 454.90 respectively. The current market cap of the company is Rs. 37675.02 crore.

The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 41.17% and 22.16% respectively.

Cipla has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA), indicating closure of the inspection at the Invagen (US) manufacturing facility. The agency had conducted inspection from December 2, 2019 to December 6, 2019.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1340.95 7.40 (0.55%)
06-May-2026 10:20 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1832.40
Dr. Reddys Lab 1284.60
Cipla 1340.95
Zydus Lifesciences 926.95
Lupin 2391.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×